(Total Views: 435)
Posted On: 05/17/2020 12:31:58 PM
Post# of 11803
It appears that none of the other companies that received EAU's put out over a dozen press releases that were misleading. The ones that were misleading were suspended by the SEC.
Wouldn't it have been more prudent to have clinical data and then have the stock value rise?
Wouldn't it have been more prudent to have clinical data and then have the stock value rise?
(1)
(0)
